drugset
drugset / Trial / NCT05737485

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

NCT05737485 ↗

Phase 1 Completed 9 enrolled ReCode Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.

Timeline

Start
2023-02-18
Primary completion
2024-07-25
Completion
2025-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject RCT1100 Messenger RNA (mRNA) — Inhaled

Indications

primary ciliary dyskinesia